Cogent Biosciences, Inc.
COGT · NASDAQ
Bulios Fair Price
$19.03
40.5% downside
Current Price
$32
According to Bulios Fair Price, COGT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Cogent Biosciences, Inc. (COGT) is an American biotechnology company focused on the development of innovative therapeutics for patients with oncological and genetic diseases. With a primary emphasis on targeted therapy and gene therapy, Cogent Biosciences aims to provide effective and personalized treatments. Their research and development efforts are centered on identifying new therapeutic targets and discovering innovative approaches to treatment. The shares of Cogent Biosciences, Inc. (COGT) may be suitable for investors seeking opportunities in the field of biotechnology and innovative therapeutics with potential in oncology and genetic diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew R. Robbins
Employees
258
Headquarters
Waltham
Upcoming events
Earnings
Upcoming earnings report